Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists

Authors

  • Sebastien J. Hotte Juravinski Cancer Centre, McMaster University
  • Antonio Finelli Princess Margaret Cancer Centre, University of Toronto
  • Kim N. Chi BC Cancer Agency, University of British Columbia
  • Christina Canil The Ottawa Hospital, University of Ottawa
  • Neil Fleshner Princess Margaret Cancer Centre, University of Toronto
  • Anil Kapoor St. Joseph’s Healthcare, McMaster University
  • Michael Kolinsky Cross Cancer Institute, University of Alberta
  • Shawn Malone The Ottawa Hospital, University of Ottawa,
  • Christopher Morash The Ottawa Hospital, University of Ottawa,
  • Tamim Niazi Jewish General Hospital, McGill University
  • Krista L. Noonan St. Joseph’s Healthcare, McMaster University
  • Michael Ong The Ottawa Hospital, University of Ottawa
  • Frederic Pouliot Centre hospitalier universitaire de Québec, Laval University
  • Bobby Shayegan St. Joseph’s Healthcare, McMaster University
  • Alan I. So Prostate Centre at Vancouver General Hospital, University of British Columbia
  • Delna Sorabji Medical Affairs, Janssen Inc
  • Huong Hew Medical Affairs, Janssen Inc
  • Laura Park-Wyllie Medical Affairs, Janssen Inc
  • Fred Saad Centre Hospitalier de l’Université de Montréal, University of Montreal

DOI:

https://doi.org/10.5489/cuaj.6779

Keywords:

oncologists, consensus, prostate-specific antigen, surveys and questionnaires, apalutamide

Abstract

Introduction: The Canadian Genitourinary Research Consortium (GURC) conducted a consensus development conference leading to 31 recommendations. Using the GURC consensus development questionnaire, we conducted a survey to measure the corresponding community-based practices on the management of metastatic castration-sensitive prostate cancer (mCSPC), metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC).

Methods: An 87-item online questionnaire was sent to 600 community urologists and oncologists involved in the treatment of prostate cancer.

Results: Seventy-two community physicians responded to the survey. Of note, 50% community physicians indicated they would treat nmCRPC with agents approved for this indication if advanced imaging showed metastases. Radiation to the prostate for low-volume mCSPC was identified as a treatment practice by 27% of community physicians, and 35% indicated docetaxel as the next line of treatment after use of apalutamide. Use of genetic testing was reported in 36% of community physicians for newly diagnosed metastatic prostate cancer.

Conclusions: There are several areas of community-based management of advanced prostate cancer that could represent potential areas for education, practice tools, and future research.

Downloads

Download data is not yet available.

Downloads

Published

2020-08-18

How to Cite

Hotte, S. J., Finelli, A., Chi, K. N., Canil, C., Fleshner, N., Kapoor, A., … Saad, F. (2020). Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists. Canadian Urological Association Journal, 15(2), E90–6. https://doi.org/10.5489/cuaj.6779

Issue

Vol. 15 No. 2 (2021): CUAJ February

Section

Original Research

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.